CG Oncology Q2 2025 Earnings Report

CG Oncology EPS Results

• Actual EPS: -$0.54
• Consensus EPS: -$0.49
• Beat/Miss: Missed by -$0.05
• One Year Ago EPS: N/A

CG Oncology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.11 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

CG Oncology Announcement Details

• Quarter: Q2 2025
• Date: 8/8/2025
• Time: Before Market Opens
• Conference Call Date: Friday, August 8, 2025
• Conference Call Time: 8:00AM ET

CG Oncology (NASDAQ:CGON) (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates. The company’s discovery engine integrates high-throughput screening, structure-based design and biomarker development, enabling rapid iteration and selection of molecules with favorable pharmacological profiles.

Since its founding, CG Oncology has built a management team with extensive experience in oncology drug development, regulatory strategy and commercial planning. The organization continues to expand its pipeline by pursuing additional immuno-oncology targets and exploring strategic collaborations to accelerate the translation of its antibody assets from preclinical research into the clinic. Through these efforts, CG Oncology aims to create differentiated therapies that address unmet needs in the treatment of solid tumor malignancies.